ZVRA logo

ZEVRA THERAPEUTICS INC

ZVRANASDAQ
๐Ÿ† #2630 by market capUS Equity
$8.75โ–ผ $0.34 (โˆ’3.74%)
Market closed ยท at close
๐Ÿ””
Track ZVRA
Get earnings, price moves & breaking news on Telegram
Track
24hโ–ผ 3.7%
7dโ€”
14dโ€”
30dโ€”
ytdโ€”
1yโ€”
๐ŸฆMarket Cap
$520M
Small Cap
๐Ÿ“ˆRevenue Growth (YoY)
75.1%
High Growth
๐Ÿ“ŠGross Margin
99.2%
High
๐Ÿ’ตFCF Margin
25.9%
Strong
โš–๏ธP/S Ratio
3.7x
Fair
Otter Score
โ€”
Insufficient data
No chart data available for ZVRA.

Trading Snapshot

Day Range
$8.70 โ€“ $9.13
52-Week Range
$8.01 โ€“ $15.04
Volume (shares)
51,547
Avg Volume (shares)
โ€”
Shares Outstanding
59.4M
Next Earnings
โ€”

Fundamentals Snapshot

Annual Revenue
โ€”
Last Q Revenue
โ€”
P/E Ratio
7.1
P/S Ratio
3.7x
EPS (TTM)
$1.29
Dividend Yield
โ€”
ZVRA logo

ZEVRA THERAPEUTICS INC

ZVRA
Financial Trends

Financial history unavailable.

StockOtter ยท stockotter.space

About ZEVRA THERAPEUTICS INC

Zevra Therapeutics, Inc., founded in 2006 and based in Celebration, Florida, is a biopharmaceutical company dedicated to discovering and developing innovative treatments for rare diseases. The company employs its proprietary Ligand Activated Therapy (LAT) technology to create novel prodrug versions of existing FDA-approved medications or to enable new applications for other compounds, primarily addressing serious medical conditions within the United States. Zevra's development pipeline is strategically concentrated on high-unmet-need therapeutic areas, including attention deficit hyperactivity disorder (ADHD), stimulant use disorder, and various rare central nervous system (CNS) conditions, such as idiopathic hypersomnia (IH). Their lead product candidate, KP1077, which is a prodrug of d-methylphenidate (known as serdexmethylphenidate), is currently in Phase II clinical trials for the treatment of both IH and narcolepsy. Another key prodrug candidate, KP879, is also advancing through Phase II studies for stimulant use disorder. In addition to its pipeline, Zevra has successfully secured FDA approval for two products: AZSTARYS, a once-daily treatment for ADHD in patients aged six years and older, and APADAZ, an immediate-release combination product containing benzhydrocodone (a prodrug of hydrocodone) and acetaminophen. The company's product portfolio also includes arimoclomol, and it holds collaboration and licensing agreements with KVK-Tech, Inc. and Commave Therapeutics SA. Formerly known as KemPharm, Inc., the company officially rebranded to Zevra Therapeutics, Inc. in February 2023.

๐Ÿฆฆ

Otter Score Breakdown

How it's scoredFive components, each rated 1โ€“5โ˜… and equally weighted (20%), averaged to a 0โ€“100 score:๐Ÿ’Ž Quality โ€” gross margin๐Ÿš€ Growth โ€” revenue YoYโš–๏ธ Valuation โ€” P/S ratioโšก Momentum โ€” 30-day price change๐Ÿ’ง Dilution โ€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

๐Ÿ’ŽQualityโ˜…โ˜…โ˜…โ˜…โ˜…
๐Ÿš€Growthโ˜…โ˜…โ˜…โ˜…โ˜…
โš–๏ธValuationโ˜…โ˜…โ˜…โ˜…โ˜…
Overall Score
Insufficient data
โ€”/100
Analyst data unavailable.

Latest News & Updates

News unavailable.